- Home
- IGMS vs ABOS Comparison
IGMS vs ABOS Comparison
Compare IGMS & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGMS
- ABOS
- Stock Information
- Founded
- IGMS 1993
- ABOS 1996
- Country
- IGMS United States
- ABOS United States
- Employees
- IGMS N/A
- ABOS N/A
- Industry
- IGMS Biotechnology: Pharmaceutical Preparations
- ABOS Biotechnology: Pharmaceutical Preparations
- Sector
- IGMS Health Care
- ABOS Health Care
- Exchange
- IGMS Nasdaq
- ABOS Nasdaq
- Market Cap
- IGMS 82.1M
- ABOS 72.7M
- IPO Year
- IGMS 2019
- ABOS 2021
- Fundamental
- Price
- IGMS $1.36
- ABOS $1.16
- Analyst Decision
- IGMS Hold
- ABOS Strong Buy
- Analyst Count
- IGMS 8
- ABOS 4
- Target Price
- IGMS $6.00
- ABOS $6.50
- AVG Volume (30 Days)
- IGMS 1.1M
- ABOS 570.9K
- Earning Date
- IGMS 08-13-2025
- ABOS 08-12-2025
- Dividend Yield
- IGMS N/A
- ABOS N/A
- EPS Growth
- IGMS N/A
- ABOS N/A
- EPS
- IGMS N/A
- ABOS N/A
- Revenue
- IGMS $2,681,000.00
- ABOS N/A
- Revenue This Year
- IGMS $134.30
- ABOS N/A
- Revenue Next Year
- IGMS $22.37
- ABOS N/A
- P/E Ratio
- IGMS N/A
- ABOS N/A
- Revenue Growth
- IGMS 27.36
- ABOS N/A
- 52 Week Low
- IGMS $0.92
- ABOS $0.86
- 52 Week High
- IGMS $22.50
- ABOS $3.60
- Technical
- Relative Strength Index (RSI)
- IGMS 59.58
- ABOS 51.76
- Support Level
- IGMS $1.12
- ABOS $1.12
- Resistance Level
- IGMS $1.39
- ABOS $1.26
- Average True Range (ATR)
- IGMS 0.08
- ABOS 0.08
- MACD
- IGMS 0.01
- ABOS -0.01
- Stochastic Oscillator
- IGMS 83.87
- ABOS 42.31
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.